Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis.
paper
Cited
Public
Unavailable
- Authors
- Hunt, Glenn E; Large, Matthew M; Cleary, Michelle; Lai, Harry Man Xiong; Saunders, John B
- Year
- 2018
- Journal
- Drug and alcohol dependence
- PMID
- 30153606
- DOI
- 10.1016/j.drugalcdep.2018.07.011
BACKGROUND: Comorbidity is highly prevalent between substance use disorders (SUDs) and schizophrenia. This systematic review and meta-analysis estimated prevalence rates of SUDs in epidemiological and treatment-seeking patients diagnosed with schizophrenia or first episode psychosis. METHODS: A literature search of Medline, EMBASE, PsycINFO and CINAHL databases was conducted from 1990 to 2017 inclusive. Prevalence of co-morbid SUDs and schizophrenia were extracted and odds ratios (ORs) were calculated using random effects meta-analysis. Combining like studies was dictated how authors reported substance use. RESULTS: There were 123 included articles with a total sample size of 165,811 subjects that yielded six epidemiological studies, 11 national or state case-registry studies, 20 large cohort studies and 86 clinical studies using in- or out-patient samples. The prevalence of any SUD was 41.7%, followed by illicit drugs (27.5%), cannabis (26.2%), alcohol (24.3%) and stimulant use (7.3%). Meta-analysis showed the pooled variance of any SUD in males was 48% which was significantly higher than that for females with schizophrenia (22.1%, OR 3.43, 95% CI 3.01, 3.92). Patients with SUD had an earlier age of onset of schizophrenia. Meta-regression showed prevalence increased over time for illicit drugs but not for other substances, including alcohol. CONCLUSIONS: The meta-analysis revealed that SUDs in schizophrenia is highly prevalent and rates have not changed over time. This indicates SUD are difficult to treat in this patient population and there is an urgent need for more informative studies to help develop better prevention, detection and treatment of SUDs in persons with schizophrenia and co-morbid disorders.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Changes in combustible cigarette and electronic nicotine delivery system use among people with and without schizophrenia spectrum disorders in the USA (2016-2023). | Johnstone S et al. | β | 2026 | β |
| Clozapine Therapy With or Without Antipsychotic Augmentation: A Retrospective Evaluation of Prescribing Practices in a Canadian Provincial Residential Treatment Centre for Concurrent Disorders: Traitement par la clozapine avec ou sans intensification Γ l'aide d'antipsychotiques : Γ©valuation rΓ©trospective des pratiques de prescription dans un centre de traitement rΓ©sidentiel provincial canadien pour les troubles concomitants. | Frankow L et al. | β | 2026 | β |
| Emotion Processing in Schizophrenia: Insights From a Brain Imaging Study Comparing Patients, Siblings, and Healthy Controls. | Fiorito AM et al. | β | 2026 | β |
| FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders. | Maddox CJ et al. | β | 2026 | β |
| Identifying drug targets for schizophrenia through gene prioritization. | Kraft J et al. | β | 2026 | β |
| Lifetime Adversity Among Individuals With Early Phase Psychosis and Comorbid Substance Misuse. | Patterson VC et al. | β | 2026 | β |
| Predicting the prognosis of primary and substance-associated psychoses using urine drug screens: A 5-year retrospective longitudinal study using medical records. | Aschenbrenner EJ et al. | β | 2026 | β |
| Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis. | Salahuddin NH et al. | β | 2026 | β |
| Substance abuse in first-episode psychosis at Chris Hani Baragwanath Hospital. | Shandu PN et al. | β | 2026 | β |
| ADHD and schizophrenia: Mere prodromal variant or homogeneous subgroup? | Schulze JB et al. | β | 2025 | β |
| All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. | Aymerich C et al. | β | 2025 | β |
| Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment. | Correll CU et al. | β | 2025 | β |
| Cannabis use and suicide in people with a diagnosis of schizophrenia: a systematic review and meta-analysis of longitudinal, case control, and cross-sectional studies. | Mulligan LD et al. | β | 2025 | β |
| Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. | Szerman N et al. | β | 2025 | β |
| Comprehensive care processes for substance use disorders in adult mental health services: A systematic review. | Reilly J et al. | β | 2025 | β |
| COPD and Schizophrenia. | Ratcliffe S et al. | β | 2025 | β |
| Differences and similarities between the genetic architecture of lifetime substance use across different substances. | Bright U et al. | β | 2025 | β |
| Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial. | Chesney E et al. | β | 2025 | β |
| Examining the genetic relationship between Alzheimer's disease, schizophrenia and their shared risk factors using genomic structural equation modelling. | Almeida E Sousa I et al. | β | 2025 | β |
| Identifying psychiatric morbidity and comorbidity patterns associated with COVID-19 mortality. A register-based cohort study from Catalonia. | Felez-Nobrega M et al. | β | 2025 | β |
| Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research. | Yoon J et al. | β | 2025 | β |
| Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough. | Correll CU | β | 2025 | β |
| Machine learning for novel phenotyping in schizophrenia. | Bareis N et al. | β | 2025 | β |
| Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments. | De Filippis S et al. | β | 2025 | β |
| Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis. | Cerveri G et al. | β | 2025 | β |
| Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. | Hong H et al. | β | 2025 | β |
| Natural, unnatural, and cause-specific mortality among current psychiatric inpatients: a systematic review and meta-analysis. | Angel-Scott H et al. | β | 2025 | β |
| Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia. | Chiappini S et al. | β | 2025 | β |
| Nurses' Perceptions of Patients With Co-Occurring Psychiatric and Substance Use Disorders in Psychiatric Settings: A Grounded Theory Study. | Bertrand E et al. | β | 2025 | β |
| Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder. | Trovini G et al. | β | 2025 | β |
| Patterns of substance use in people with severe mental illness: A case-control study in Ethiopia. | Alemayehu M et al. | β | 2025 | β |
| Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study. | Swerdlow NR et al. | β | 2025 | β |
| Preferences for Mobile Apps That Aim to Modify Alcohol Use: Thematic Content Analysis of User Reviews. | Kirouac M et al. | β | 2025 | β |
| Problematic gambling and alcohol misuse among adults in Japan. | Stickley A et al. | β | 2025 | β |
| Psychopathic Traits Associate With Later Schizophrenia. | Vaurio O et al. | β | 2025 | β |
| Psychosocial interventions for people with comorbid substance use disorders in people with severe mental health conditions in low- and middle-income countries: scoping review. | Mihretu A et al. | β | 2025 | β |
| Psychostimulant Substitution Therapy for the Treatment of Stimulant Use Disorders in Patients with Schizophrenia or Schizoaffective Disorder: A Systematic Review. | Ramasubbu C et al. | β | 2025 | β |
| Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder. | Brunette MF et al. | β | 2025 | β |
| Real-World Prescribing Patterns of Long-Acting Injectable Antipsychotics in Australian Psychiatric Inpatients: Trends, Clinical Outcomes, and Substance Use Prevalence. | Akindele T et al. | β | 2025 | β |
| Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study. | Vano LJ et al. | β | 2025 | β |
| Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis. | Herder T et al. | β | 2025 | β |
| Substance Use Disorder Among Patients with Primary Mental Illnesses in Southwestern Uganda. | Rubega A et al. | β | 2025 | β |
| Substance use disorders, severe mental illness and risk of reoffending among women released from prison: a national cohort study. | Svendsen V et al. | β | 2025 | β |
| Symptom severity and cognitive performance in patients with substance induced psychotic disorder and schizophrenia: a cross-sectional comparative study. | Stoychev K et al. | β | 2025 | β |
| Targeted and Non-Targeted Metabolomic Evaluation of Cerebrospinal Fluid in Early Phase Schizophrenia: A Pilot Study from the Hopkins First Episode Psychosis Project. | Jaskiw GE et al. | β | 2025 | β |
| Transitions in mental health care utilisation at GHU Paris between 2019 and 2024: A post-pandemic perspective. | Perozziello A et al. | β | 2025 | β |
| A comprehensive update on genetic inheritance, epigenetic factors, associated pathology, and recent therapeutic intervention by gene therapy in schizophrenia. | R R et al. | β | 2024 | β |
| Assessing Cannabis Use in People with Psychosis. | Chesney E et al. | β | 2024 | β |
| Association of duration of treatment on post-discharge mortality in forensic psychiatric patients in Finland. | Ojansuu I et al. | β | 2024 | β |
| Avatar Intervention in Virtual Reality for Cannabis Use Disorder in Individuals With Severe Mental Disorders: Results From a 1-Year, Single-Arm Clinical Trial. | Giguere S et al. | β | 2024 | β |
| Cancer mortality and morbidity among patients with schizophrenia: A hospital-based cohort study, 1992-2020. | Drevinskaite M et al. | β | 2024 | β |
| Cannabis cravings predict cigarette use in schizophrenia: a secondary analysis from two cannabis abstinence studies. | Johnstone S et al. | β | 2024 | β |
| Certified Community Behavioral Health Clinic Services for Clients With Co-occurring Disorders: A Latent Class Approach. | Hu Y et al. | β | 2024 | β |
| Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity. | Adan A et al. | β | 2024 | β |
| Comorbidity Burden and Health Care Utilization by Substance use Disorder Patterns among People with HIV in Florida. | Liu Y et al. | β | 2024 | β |
| Conceptualization and characterization of "primary" and "secondary" cognitive impairment in schizophrenia. | Vita A et al. | β | 2024 | β |
| Contingency Management for Dually Diagnosed Inpatients with Psychosis. | Docx L et al. | β | 2024 | β |
| Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations. | Vita A et al. | β | 2024 | β |
| Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies. | Sajatovic M et al. | β | 2024 | β |
| Establishing associated risk factors, including fungal and parasitic infections among Malaysians living with schizophrenia. | Franklin F et al. | β | 2024 | β |
| Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation. | Cavallotto C et al. | β | 2024 | β |
| Examining the impact of substance use on hospital length of stay in schizophrenia spectrum disorder: a retrospective analysis. | Burrer A et al. | β | 2024 | β |
| Exercise or mind-body exercises for psychiatry symptoms and quality of life in schizophrenia spectrum and other psychotic disorders: an overview of systematic reviews with meta-analysis. | Martinez-Calderon J et al. | β | 2024 | β |
| Exploring barriers and facilitators to addressing hazardous alcohol use and AUD in mental health services: a qualitative study among Dutch professionals. | Kools N et al. | β | 2024 | β |
| Factors influencing the length of stay in forensic psychiatric settings: a systematic review. | Dima A et al. | β | 2024 | β |
| Family Caregivers' Trajectories of Distress While Caring for a Person With Serious Mental Illness. | Kalhovde AM et al. | β | 2024 | β |
| Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders. | KΓ€mpe A et al. | β | 2024 | β |
| Identification and treatment of individuals with childhood-onset and early-onset schizophrenia. | Correll CU et al. | β | 2024 | β |
| Influence of perceived harm due to substance use on the relationships between positive psychotic experiences and suicidal experiences in people with non-affective psychosis. | Gooding P et al. | β | 2024 | β |
| Institutional influence on length of stay in German forensic hospitals: a multilevel analysis of patients with schizophrenia spectrum disorders. | StΓΌrner L et al. | β | 2024 | β |
| Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable. | Vessels T et al. | β | 2024 | β |
| Management of schizophrenia and comorbid substance use disorders: expert review and guidance. | Neyra A et al. | β | 2024 | β |
| Multimorbidity and the Etiology of Schizophrenia. | Szoke A et al. | β | 2024 | β |
| Navigating Nutritional Inequality in Schizophrenia: A Comprehensive Exploration of Diet, Genetics, and Holistic Management Across the Life Cycle. | Yan Y et al. | β | 2024 | β |
| New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment. | Faris P et al. | β | 2024 | β |
| Opinions of French psychiatrists on the regulatory status of cannabis: Results from the "PsyCan - EncΓ©phale" national online survey. | Leclerc L et al. | β | 2024 | β |
| Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. | Agid O et al. | β | 2024 | β |
| Physical, sexual and overall reported interpersonal violence against adult out-patients with severe mental illness under remission, receiving healthcare at Butabika hospital: A cross-sectional study. | Guma EI et al. | β | 2024 | β |
| Predictors and shared traits of longevity within 1 year before death in patients with schizophrenia receiving long-term care: 3-year retrospective cross-sectional study. | Yu CH et al. | β | 2024 | β |
| Prevalence of substance use among a sample of patients attending an outpatient psychiatric clinic in Amman, Jordan. | Abbasi LN et al. | β | 2024 | β |
| Problem gambling in psychotic disorders: A systematic review and meta-analysis of prevalence. | Corbeil O et al. | β | 2024 | β |
| Psychosis associated with cannabis withdrawal: systematic review and case series. | Chesney E et al. | β | 2024 | β |
| Psychosocial Interventions for Individuals With Comorbid Psychosis and Substance Use Disorders: Systematic Review and Meta-analysis of Randomized Studies. | Siddiqui S et al. | β | 2024 | β |
| Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug. | Dell'Osso L et al. | β | 2024 | β |
| Risk Factors of Alcohol Use Disorders Among Inpatients with Schizophrenia: An Institutional-Based Cross-sectional Survey. | Li B et al. | β | 2024 | β |
| Sex differences in prevalence and clinical correlates of internet addiction among Chinese adolescents with schizophrenia. | Zhong Y et al. | β | 2024 | β |
| Sociodemographic and treatment-related determinants of recent substance use among adults with comorbid substance misuse and psychotic disorders discharged from substance use treatment. | Moore J et al. | β | 2024 | β |
| Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in the UK. | Mulligan LD et al. | β | 2024 | β |
| Substance Use Within Trials of Psychological Interventions for Psychosis: Sample Inclusion, Secondary Measures, and Intervention Effectiveness. | Halsall L et al. | β | 2024 | β |
| TAPS-tool reveals severe under detection of substance use problems in patients with severe mental illness. | Seelen-de Lang B et al. | β | 2024 | β |
| The impact of lifetime substance use on psychiatric comorbidities and treatment seeking in patients with alcohol use disorders. | Engelgardt P et al. | β | 2024 | β |
| The prevalence and comorbidity of mental health and substance use disorders in Scandinavian prisons 2010-2019: a multi-national register study. | Bukten A et al. | β | 2024 | β |
| The relationship between substance use and self-reported aspects of social functioning in patients with a psychotic disorder. | van der Heijden HS et al. | β | 2024 | β |
| The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. | Tandon R et al. | β | 2024 | β |
| The Whys and Wherefores of Reducing Cannabis Use in Early Psychosis: A Qualitative Study of Service Users<i>'</i> Experiences of Quitting and the Support. | Sheridan Rains L et al. | β | 2024 | β |
| Understanding social and clinical associations with unemployment for people with schizophrenia and bipolar disorders: large-scale health records study. | Chilman N et al. | β | 2024 | β |
| Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia. | Lesh TA et al. | β | 2024 | β |
| When do drugs trigger criminal behavior? a machine learning analysis of offenders and non-offenders with schizophrenia and comorbid substance use disorder. | Bender EM et al. | β | 2024 | β |
| Workforce estimate to treat mental disorders in the Kingdom of Saudi Arabia. | Lee E et al. | β | 2024 | β |
| Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders. | Pardo M et al. | β | 2023 | β |
| A latent class analysis of mental disorders, substance use, and aggressive antisocial behavior among Swedish forensic psychiatric patients. | Green J et al. | β | 2023 | β |
| A meta-analysis of the neural substrates of monetary reward anticipation and outcome in alcohol use disorder. | Zeng J et al. | β | 2023 | β |
| A Mobile Health App (ChillTime) Promoting Emotion Regulation in Dual Disorders: Acceptability and Feasibility Pilot Study. | Pennou A et al. | β | 2023 | β |
| A Qualitative Study of Emergency Physicians' and Nurses' Experiences Caring for Patients With Psychiatric Conditions and/or Substance Use Disorders. | Isbell LM et al. | β | 2023 | β |
| Are migrants diagnosed with a trauma-related disorder at risk of premature mortality? A register-based cohort study in Denmark. | Bager L et al. | β | 2023 | β |
| Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals. | Argote M et al. | β | 2023 | β |
| Association Between Retinal Features From Multimodal Imaging and Schizophrenia. | Wagner SK et al. | β | 2023 | β |
| Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study. | Rafizadeh R et al. | β | 2023 | β |
| Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data. | Patel R et al. | β | 2023 | β |
| Avatar Intervention for Cannabis Use Disorder in Individuals with Severe Mental Disorders: A Pilot Study. | GiguΓ¨re S et al. | β | 2023 | β |
| Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. | Gouse BM et al. | β | 2023 | β |
| Caring for youth with co-occurring substance use and severe psychiatric disorders: diagnostic challenges and clinical implications. | Keramatian K et al. | β | 2023 | β |
| Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis. | Rafizadeh R et al. | β | 2023 | β |
| Efficacy of Psychosocial and Psychological Interventions in Addition to Drug Therapy to Improve Global Functioning of Inpatients with Schizophrenia Spectrum and Mood Disorders: A Real-World Observational Study. | Chiappini S et al. | β | 2023 | β |
| Ethanol and illicit drugs acute use and abuse as risk factors for suicide: A case-control study based on forensic autopsies in the Basque Country, Spain. | Morentin B et al. | β | 2023 | β |
| Extracellular Vesicles in Mental Disorders: A State-of-art Review. | Kong L et al. | β | 2023 | β |
| Gender and addiction and other mental disorders comorbidity: sociodemographic, clinical, and treatment differences. | FernΓ‘ndez SD et al. | β | 2023 | β |
| Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. | Solmi M et al. | β | 2023 | β |
| Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. | Johnson EC et al. | β | 2023 | β |
| Letters to the Editor: Letter to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia'. | Nair PC et al. | β | 2023 | β |
| Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community. | Vita A et al. | β | 2023 | β |
| Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment. | Solmi M et al. | β | 2023 | β |
| Neurobehavioral risk factors influence prevalence and severity of hazardous substance use in youth at genetic and clinical high risk for psychosis. | Amir CM et al. | β | 2023 | β |
| Outcomes Among People With Schizophrenia Participating in General-Population Smoking Cessation Treatment: An Observational Study. | Veldhuizen S et al. | β | 2023 | β |
| Predictors of Functioning and Recovery Among Men and Women Veterans with Schizophrenia. | Goodsmith N et al. | β | 2023 | β |
| Prevalence of lifestyle cardiovascular risk factors and estimated framingham 10-year risk scores of adults with psychotic disorders compared to controls at a referral hospital in Eldoret, Kenya. | Kwobah E et al. | β | 2023 | β |
| Prevalence of mental disorders in South Asia: A systematic review of reviews. | Vidyasagaran AL et al. | β | 2023 | β |
| Psychiatric and non-psychiatric drugs causing false-positive amphetamines urine test in psychiatric patients: a pharmacovigilance analysis using FAERS. | Battini V et al. | β | 2023 | β |
| Risk for alcohol use problems in severe mental illness: Interactions with sex and racial/ethnic minority status. | Levit JD et al. | β | 2023 | β |
| Risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 mortality in people with pre-existing mental disorders: an umbrella review. | Bertolini F et al. | β | 2023 | β |
| Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics, disability and quality of life. | Sood M et al. | β | 2023 | β |
| Substance use outcomes among individuals with severe mental illnesses receiving assertive community treatment: A systematic review. | Abufarsakh B et al. | β | 2023 | β |
| Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report. | Sahlsten SchΓΆlin J et al. | β | 2023 | β |
| The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia. | Matuszewska A et al. | β | 2023 | β |
| The influence of dopamine autoreceptors on temperament and addiction risk. | Zald DH | β | 2023 | β |
| The Medication Use Issues and Challenges of Mental Illness Exacerbation in Patients with Schizophrenia: A Qualitative Study in Thailand. | Klinpiboon P et al. | β | 2023 | β |
| The Modulated Role of <i>Toxoplasma gondii</i> on Eosinophils in Psychiatric Disorders after Cannabis Cessation. | Romeo B et al. | β | 2023 | β |
| The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated. | Kayir H et al. | β | 2023 | β |
| "They Just Helped Save My Life:" Client Perspectives on the Los Angeles County Full Service Partnership (FSP) Program for Serious Mental Illness. | Erickson BR et al. | β | 2023 | β |
| Time trends in co-occurring substance use and psychiatric illness (dual diagnosis) from 2000 to 2017 - a nationwide study of Danish register data. | MΓ₯rtensson S et al. | β | 2023 | β |
| [Toward a better understanding of fatigue in schizophrenia]. | Mulin E et al. | β | 2023 | β |
| Transcriptome-wide association study by different approaches reveals candidate causal genes for cannabis use disorder. | Gao J et al. | β | 2023 | β |
| Trends in CV mortality among patients with known mental and behavioral disorders in the US between 1999 and 2020. | Ebert T et al. | β | 2023 | β |
| What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. | Baeza I et al. | β | 2023 | β |
| Workforce Estimate to Treat Mental Disorders in the Kingdom of Saudi Arabia | Lee E et al. | β | 2023 | β |
| A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. | Orsolini L et al. | β | 2022 | β |
| A cross-sectional study of current and lifetime sexual hallucinations and delusions in Lebanese patients with schizophrenia: frequency, characterization, and association with childhood traumatic experiences and disease severity. | Gerges S et al. | β | 2022 | β |
| Association between formal thought disorder and cannabis use: a systematic review and meta-analysis. | Argote M et al. | β | 2022 | β |
| Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. | LΓ€hteenvuo M et al. | β | 2022 | β |
| A systematic review of the perceptions and attitudes of mental health nurses towards alcohol and other drug use in mental health clients. | Merrick TT et al. | β | 2022 | β |
| Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. | Chesney E et al. | β | 2022 | β |
| Cannabidiol for the treatment of autism spectrum disorder: hope or hype? | Pedrazzi JFC et al. | β | 2022 | β |
| Cannabis Cessation, Inflammatory Markers and Schizophrenia. | Romeo B et al. | β | 2022 | β |
| Changes in co-occurring substance diagnosis among patients admitted to psychiatric treatment over a twenty-year period. | MΓ₯rtensson S et al. | β | 2022 | β |
| Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis. | Jiang Y et al. | β | 2022 | β |
| Deficit Symptomatology of Schizophrenia Is Associated with Attenuated Taste Identification: Findings from a Cross-Sectional Study. | WroΕski M et al. | β | 2022 | β |
| Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic. | Busch AB et al. | β | 2022 | β |
| Dropout Rates in Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse: A Systematic Review and Meta-Analysis. | Bouchard M et al. | β | 2022 | β |
| Effectiveness of nutrition and dietary interventions for people with serious mental illness: systematic review and meta-analysis. | Rocks T et al. | β | 2022 | β |
| Establishment and application value of a novel prescription medication abuse monitoring model for psychiatric hospitals. | Du Z et al. | β | 2022 | β |
| Exploring the trend of Schizophrenia at Hiwot Fana specialized university referral hospital, Eastern, Ethiopia (2016-2020): A 5-year retrospective analysis. | Mohammed F et al. | β | 2022 | β |
| Gastrointestinal and liver disease in patients with schizophrenia: A narrative review. | Grant RK et al. | β | 2022 | β |
| Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis. | Rault O et al. | β | 2022 | β |
| In-patient psychiatric care and non-substance-related psychiatric diagnoses among individuals seeking treatment for alcohol and substance use disorders: associations with all-cause mortality and suicide. | Levola J et al. | β | 2022 | β |
| Internalized stigma in patients with schizophrenia: A hospital-based cross-sectional study from Nepal. | Dhungana S et al. | β | 2022 | β |
| Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. | Bidzinski KK et al. | β | 2022 | β |
| It might be a wonderful opportunity when patients with a psychotic disorder use cannabis. | de Haan L | β | 2022 | β |
| Network Analysis of the Structure of the Core Symptoms and Clinical Correlates in Comorbid Schizophrenia and Gambling Disorder. | Granero R et al. | β | 2022 | β |
| Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis. | Johnstone S et al. | β | 2022 | β |
| Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review. | Johnstone S et al. | β | 2022 | β |
| Olanzapine and samidorphan combination treatment: A systematic review. | Jawad MY et al. | β | 2022 | β |
| Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance. | Greco LA et al. | β | 2022 | β |
| Patients with Schizophrenia Showed Worse Cognitive Performance than Bipolar and Major Depressive Disorder in a Sample with Comorbid Substance Use Disorders. | Marquez-Arrico JE et al. | β | 2022 | β |
| Prevalence of cannabis use in people with psychosis in KwaZulu-Natal, South Africa. | Mona K et al. | β | 2022 | β |
| Profiles and factors associated with schizophrenia in eastern Ethiopia: A matched case-control study. | Mohammed F et al. | β | 2022 | β |
| Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response. | Adan A et al. | β | 2022 | β |
| Psychosis and Hopelessness Mediate the Relationship Between Reduced Sleep and Suicidal Ideation in Schizophrenia Spectrum Disorders. | Carruthers SP et al. | β | 2022 | β |
| Referral to aftercare following inpatient withdrawal treatment and readmission: retrospective chart review of patients with substance use disorders. | Habermeyer B et al. | β | 2022 | β |
| Reliability of self-report of cannabis use among patients with schizophrenia. | Rammouz I et al. | β | 2022 | β |
| Risks of major mental disorders after parental death in children, adolescents, and young adults and the role of premorbid mental comorbidities: a population-based cohort study. | Li DJ et al. | β | 2022 | β |
| Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. | Γlamo C | β | 2022 | β |
| Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects. | Orsolini L et al. | β | 2022 | β |
| Selection bias in clinical studies of first-episode psychosis: A follow-up study. | Walta M et al. | β | 2022 | β |
| Smoking Addiction in Patients with Schizophrenia Spectrum Disorders and Its Perception and Intervention in Healthcare Personnel Assigned to Psycho-Rehabilitation Programs: A Qualitative Research. | Caponnetto P et al. | β | 2022 | β |
| Substance Use in Relation to Mental Illness: A Study of Mexican-Origin Latinos with Schizophrenia and Their Family Members. | Hernandez M et al. | β | 2022 | β |
| The pharmacological treatment of schizophrenia: How far have we come? | Rubio JM et al. | β | 2022 | β |
| The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis. | Baranyi G et al. | β | 2022 | β |
| The role of attachment, coping style and reasons for substance use in substance users with psychosis. | Berry K et al. | β | 2022 | β |
| The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. | Arango C et al. | β | 2022 | β |
| Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System. | Leconte C et al. | β | 2022 | β |
| Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. | Margolese HC et al. | β | 2022 | β |
| Validity and usefulness of the short form of the Drinking Motives Questionnaire Revised (DMQ-R SF) among patients with schizophrenia. | Gierski F et al. | β | 2022 | β |
| White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis. | Rasmussen JΓ et al. | β | 2022 | β |
| Addressing Dual Disorders in a Medium-Term Admission Unit. | Arnau F et al. | β | 2021 | β |
| Agitation in schizophrenia: origins and evidence-based treatment. | Citrome L | β | 2021 | β |
| Alcohol use disorder and its determinant factors among patients with schizophrenia attending treatment at mental specialized hospital, Addis Ababa, Ethiopia: A cross-sectional study. | Tadesse H et al. | β | 2021 | β |
| Algorithm-Driven Substance Use Disorder Treatment for Inner-City Clients With Serious Mental Illness and Multiple Impairments. | McHugo GJ et al. | β | 2021 | β |
| Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use. | Wiedmann M et al. | β | 2021 | β |
| Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study. | KΓΆck P et al. | β | 2021 | β |
| Cannabis use and cannabis use disorder. | Connor JP et al. | β | 2021 | β |
| Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction. | Rodriguez Cruz J et al. | β | 2021 | β |
| Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder. | Meyer M et al. | β | 2021 | β |
| Differential dopamine release by psychosis-generating and non-psychosis-generating addictive substances in the nucleus accumbens and dorsomedial striatum. | Danielsson K et al. | β | 2021 | β |
| Early-life lead exposure and neurodevelopmental disorders. | Albores-Garcia D et al. | β | 2021 | β |
| Effects of comorbid alcohol use disorder on the clinical outcomes of first-episode schizophrenia: a nationwide population-based study. | Ahn S et al. | β | 2021 | β |
| Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. | GarcΓa-Carmona JA et al. | β | 2021 | β |
| Infections, antibiotic treatment and the Microbiome in relation to schizophrenia. | Klein-Petersen AW et al. | β | 2021 | β |
| Investigating the association between temperature and hospital admissions for major psychiatric diseases: A study in Greece. | Asimakopoulos LO et al. | β | 2021 | β |
| Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. | Coles AS et al. | β | 2021 | β |
| Meta-Analysis on the Effect of Contingency Management for Patients with Both Psychotic Disorders and Substance Use Disorders. | Destoop M et al. | β | 2021 | β |
| Morbidity and mortality in schizophrenia with comorbid substance use disorders. | LΓ€hteenvuo M et al. | β | 2021 | β |
| Multimorbidity and vulnerability among those living with psychosis in Indigenous populations in Cape York and the Torres Strait. | Charlson F et al. | β | 2021 | β |
| Natural cause mortality of mental health consumers: A 10-year retrospective cohort study. | Suggett J et al. | β | 2021 | β |
| News and social media coverage is associated with more downloads and citations of manuscripts that focus on substance use. | Palamar JJ et al. | β | 2021 | β |
| Personality Traits in Individuals with the Dual Diagnosis of Psychosis and Substance Use Disorders: A Comprehensive Review and Meta-Analysis. | Oh H et al. | β | 2021 | β |
| Premorbid functioning in schizophrenia spectrum disorders with comorbid substance use: A systematic review. | Prat G et al. | β | 2021 | β |
| Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia. | Temmingh H et al. | β | 2021 | β |
| Prevalence of Substance Use among Psychotic Patients and Determining Its Strongest Predictor. | Mousavi SB et al. | β | 2021 | β |
| Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder. | Mazumder AH et al. | β | 2021 | β |
| Schizophrenia and substance use disorder: Characteristics of coexisting issues in a forensic setting. | Patterson A et al. | β | 2021 | β |
| The association of cannabis use with quality of life and psychosocial functioning in psychosis. | Bruins J et al. | β | 2021 | β |
| The association of polygenic risk for schizophrenia, bipolar disorder, and depression with neural connectivity in adolescents and young adults: examining developmental and sex differences. | Meyers JL et al. | β | 2021 | β |
| Transgenerational evidence of increases in dopamine D2 receptor sensitivity in rodents: Impact on sensorimotor gating, the behavioral response to nicotine and BDNF. | Gill WD et al. | β | 2021 | β |
| Unraveling the Association Between Schizophrenia and Substance Use Disorder-Predictors, Mechanisms and Treatment Modifications: A Systematic Review. | Masroor A et al. | β | 2021 | β |
| Validity of Short-Term Assessment of Risk and Treatability in the Japanese Forensic Probation Service. | Kikuchi A et al. | β | 2021 | β |
| A 16-year follow-up of patients with serious mental illness and co-occurring substance use disorder. | Drake RE et al. | β | 2020 | β |
| Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice. | Qin Z et al. | β | 2020 | β |
| A Qualitative Systematic Review of Caregivers' Experiences of Caring for Family Diagnosed with Schizophrenia. | Cleary M et al. | β | 2020 | β |
| Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. | Ghabrash MF et al. | β | 2020 | β |
| Comparison of the effectiveness of a 12 step substance use recovery program on quality of life. | Mokhtari MR et al. | β | 2020 | β |
| Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study. | Patel RS et al. | β | 2020 | β |
| Early onset of cannabis use and violent behavior in psychosis. | Moulin V et al. | β | 2020 | β |
| Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia. | Berry A et al. | β | 2020 | β |
| Extracellular vesicles in patients in the acute phase of psychosis and after clinical improvement: an explorative study. | Tunset ME et al. | β | 2020 | β |
| Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. | Coyle JT et al. | β | 2020 | β |
| From apathy to addiction: Insights from neurology and psychiatry. | Kirschner M et al. | β | 2020 | β |
| Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study. | GarcΓa-Carmona JA et al. | β | 2020 | β |
| New discoveries for an old drug: a review of recent olanzapine research. | Meftah AM et al. | β | 2020 | β |
| Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. | Szerman N et al. | β | 2020 | β |
| Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia. | Fochtmann LJ et al. | β | 2020 | β |
| Predicting factors for non-suicidal self-injury in patients with schizophrenia spectrum disorders and the role of substance use. | GΓΌney E et al. | β | 2020 | β |
| Prevalence and clinical correlates of substance use amongst acute psychiatric inpatients in Gauteng, South Africa. | Anic A et al. | β | 2020 | β |
| Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. | Hunt GE et al. | β | 2020 | β |
| Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015. | Maloney-Hall B et al. | β | 2020 | β |
| Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations. | Vadukapuram R et al. | β | 2020 | β |
| Schizophrenia. | Hasan A et al. | β | 2020 | β |
| Schizophrenia and the retina: Towards a 2020 perspective. | Silverstein SM et al. | β | 2020 | β |
| Sexual health of women with schizophrenia: A review. | Barker LC et al. | β | 2020 | β |
| Substance Use Patterns and Schizophrenia Spectrum Disorders: A Retrospective Study of Inpatients at a Community Teaching Hospital. | Tumenta T et al. | β | 2020 | β |
| Temperament and Character Profile and Its Clinical Correlates in Male Patients with Dual Schizophrenia. | RΓo-MartΓnez L et al. | β | 2020 | β |
| The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. | Keepers GA et al. | β | 2020 | β |
| The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. | Keepers GA et al. | β | 2020 | β |
| The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. | Kozloff N et al. | β | 2020 | β |
| The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: a population-based cohort study. | Pettersson D et al. | β | 2020 | β |
| The relationship between hopelessness and risk factors for early mortality in people with a lived experience of a serious mental illness. | Fortuna KL et al. | β | 2020 | β |
| Visual-Tactile Spatial Multisensory Interaction in Adults With Autism and Schizophrenia. | Noel JP et al. | β | 2020 | β |
| Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder. | Archibald L et al. | β | 2019 | β |
| Coping Strategies in Male Patients under Treatment for Substance Use Disorders and/or Severe Mental Illness: Influence in Clinical Course at One-Year Follow-Up. | Marquez-Arrico JE et al. | β | 2019 | β |
| Effects of chronic physical illness on treatment outcomes among patients with schizophrenia. | Ε imunoviΔ FilipΔiΔ I et al. | β | 2019 | β |
| Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. | Krause M et al. | β | 2019 | β |
| Integrating Treatment for Co-Occurring Mental Health Conditions. | Yule AM et al. | β | 2019 | β |
| Psychosocial interventions for people with both severe mental illness and substance misuse. | Hunt GE et al. | β | 2019 | β |
| Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. | Teal LB et al. | β | 2019 | β |
| Sex Differences in Clinical and Functional Outcomes among Patients Treated in an Early Intervention Service for Psychotic Disorders: An Observational Study. | Dama M et al. | β | 2019 | β |
| The impact of substance use on treatment as a compulsory patient. | Vine R et al. | β | 2019 | β |
| The Penrose Effect and its acceleration by the war on drugs: a crisis of untranslated neuroscience and untreated addiction and mental illness. | Grecco GG et al. | β | 2019 | β |
| The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. | Pinto JV et al. | β | 2019 | β |
| Treatment of substance use disorders with co-occurring severe mental health disorders. | Murthy P et al. | β | 2019 | β |
| Ξ<sup>9</sup>-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation. | Lecca S et al. | β | 2019 | β |